Transitioning eligible VTE patients to a DOAC

Given the current pressures on healthcare services including anticoagulation services, we would like to offer some information which may support you in managing your DVT & PE patients and reduce the need for additional clinic or pharmacy visits.

Warfarin/LWMH Transition Guide

Following the publication of Government (NHS England) guidance2, endorsed by the British Haematological Society, the Royal Pharmaceutical Society and the Primary Care Pharmacy Association, to transition patients from VKA to a DOAC, we have developed some resources to support this transition. Please find below a link to download a simple guide for transitioning from VKA or LWMH to rivaroxaban for your patients undergoing anticoagulation treatment for confirmed DVT/PE or continued treatment for secondary prevention.

Latest NICE VTE Guidelines March 2020 recommend the use of DOACs for confirmed proximal DVT or PE (including patients with active cancer) and for long term anticoagulation to prevent VTE recurrence.3

The Einstein PE & DVT trials provide evidence for the use of rivaroxaban in acute treatment, and the Einstein CHOICE trial showed rivaroxaban, both treatment dose (20mg) and a thromboprophylactic dose (10 mg) to be superior to aspirin 100mg for preventing VTE recurrence associated with a rate of bleeding similar to that with aspirin (<1% of patients experienced major bleeding).4-6

VTE patients can now access resources digitally via the patient area of the website, click here to see more.

Rivaroxaban Treatment Initiation Pack

For newly diagnosed DVT and PE patients, the initiation pack for rivaroxaban is available to simplify the first month of treatment. This pack includes three weeks of the 15mg b.d. dose, optimally protecting patients during the initial high-risk period7, and one week of the reduced dose (20mg o.d.) for continued treatment, thereby removing the need for an additional hospital visit to reduce the dose. Patients can be maintained on this dose for 3-6 months based on an individual patient’s assessed risk.1*

Initiation Starter Pack

If you'd like additional support or for more information on how to optimally manage VTE patients with rivaroxaban, speak to your local Bayer representative.

PE – pulmonary embolism; DVT – deep vein thrombosis; VTE – venous thromboembolism; DOACs – direct oral anticoagulants; NICE – National Institute for Health and Care Excellence. LWMH; low weight molecular heparin.

* Please refer to the SmPC for full prescribing information

1. Xarelto (rivaroxaban). Summary of Product Characteristics, as approved by the European Commission
2. Royal Pharmaceutical Society Accessed 30 March 2020.
3. NICE. 2020. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing [NG158]. Accessed April 2020
4. Bauersachs R., et al. N Engl J Med. 2010; 363(26):2499-510
5. Büller HR, et al. N Engl J Med. 2012;366(14):1287-97
6. Weitz JI, et al. N Engl J Med 2017; 376(12):1211-22
7. Limone BL, et al. Thromb Res. 2013;132:420-426

We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.

Reporting adverse events and quality complaints

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email:

Further information is available on the "contact" tab at